A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington’s disease

Background Huntington’s disease (HD) is a neurodegenerative disorder caused by the expansion of the CAG repeat in the huntingtin ( HTT ) gene. When the number of CAG repeats exceeds 36, the translated expanded polyglutamine-containing HTT protein (mutant HTT [mHTT]) interferes with the normal functi...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of neuroinflammation Ročník 19; číslo 1; s. 56 - 17
Hlavní autori:	Chen, Kai-Po, Hua, Kuo-Feng, Tsai, Fu-Ting, Lin, Ting-Yu, Cheng, Chih-Yuan, Yang, Ding-I., Hsu, Hsien-Ta, Ju, Tz-Chuen
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	London BioMed Central 26.02.2022 BioMed Central Ltd BMC
Predmet:	Animals Biomedical and Life Sciences Biomedicine Disease Models, Animal Genetic aspects Huntington Disease - drug therapy Huntington Disease - genetics Huntington Disease - metabolism Huntington's chorea Huntington’s disease (HD) Immunology Inflammasomes - therapeutic use Interleukin‐1β (IL‐1β) Male Mice Mice, Transgenic Mutated huntingtin (mHTT) Neurobiology Neurodegenerative Diseases Neurology Neuroprotection Neurosciences NLR Family, Pyrin Domain-Containing 3 Protein - metabolism Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Patient outcomes Prevention Taiwan Nucleotide oligomerization domain-like receptor protein 3 inflammasome (NLRP3 inflammasome) Huntington’s disease (HD) Interleukin‐1β (IL‐1β) Mutated huntingtin (mHTT)
ISSN:	1742-2094, 1742-2094
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!